Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;25(2):585-591.
doi: 10.1007/s12253-018-0475-8. Epub 2018 Oct 29.

ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma

Ulana Kotowski  1 , Lorenz Kadletz  1 , Sven Schneider  1 , Felicitas Oberndorfer  2 , Boban M Erovic  1 , Matthaeus Ch Grasl  1 , Claudia Lill  3 , Gregor Heiduschka  1
Affiliations

ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma

Ulana Kotowski et al. Pathol Oncol Res. 2019 Apr.

Abstract

Engulfment and cell motility 3 protein (ELMO3) is a protein that is involved in cell migration and promotes the remodeling of the cytoskeleton. Moreover, it is described as a prognostic marker in several cancers. The aim of this study was to evaluate ELMO3 expression in patients with minor salivary gland carcinoma. The expression of ELMO3 was examined by immunohistochemistry. The intensity of staining was evaluated and data was correlated to clinical outcome. Forty-six patients with complete clinical data were included into statistical analysis. ELMO3 expression was observed in 85% of the cases. High staining intensity of ELMO3 correlated with a significantly worse disease free survival (p = .0495) and a higher recurrence rate (p = .0071). In conclusion, it is still difficult to predict the clinical outcome of patients with minor salivary gland carcinoma. Evaluation of ELMO3 might serve as a clinical prognostic marker in future.

Keywords: ELMO3; Immunohistochemistry; Minor salivary gland cancer; Molecular prognostic marker.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Immunohistochemical expression analysis of ELMO3 in samples from patients with minor salivary gland carcinoma. Examples of tumors with (a) no, (b) weak, (c) moderate and (d) strong ELMO3 expression
Fig. 2
Fig. 2
Kaplan-Meier estimates for (a) overall survival (OS) and (b) disease-free survival (DFS) according to ELMO3 expression intensity in patients with minor salivary gland cancer
Fig. 3
Fig. 3
(a) Survival and (b) recurrence rates after total follow up according to ELMO3 expression intensity in patients with minor salivary gland cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Strick MJ, Kelly C, Soames JV, McLean NR. Malignant tumours of the minor salivary glands--a 20 year review. Br J Plast Surg. 2004;57:624–631. doi: 10.1016/j.bjps.2004.04.017. - DOI - PubMed
    1. Barnes L, World Health Organization, International Agency for Research on Cancer (2005) Pathology and genetics of head and neck Tumours. IARC
    1. Jones AS, Beasley NJ, Houghton DJ, Helliwell TR, Husband DJ. Tumours of the minor salivary glands. Clin Otolaryngol Allied Sci. 1998;23:27–33. doi: 10.1046/j.1365-2273.1998.00088.x. - DOI - PubMed
    1. Lopes MA, Santos GC, Kowalski LP. Multivariate survival analysis of 128 cases of oral cavity minor salivary gland carcinomas. Head Neck. 1998;20:699–706. doi: 10.1002/(SICI)1097-0347(199812)20:8<699::AID-HED7>3.0.CO;2-P. - DOI - PubMed
    1. Vander Poorten VL, Balm AJ, Hilgers FJ, et al. Stage as major long term outcome predictor in minor salivary gland carcinoma. Cancer. 2000;89:1195–1204. doi: 10.1002/1097-0142(20000915)89:6<1195::AID-CNCR2>3.0.CO;2-J. - DOI - PubMed

MeSH terms